Century Therapeutics Inc (IPSC) Actualités

Form S-3 - Registration statement under Securities Act of 1933

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 8-K - Current report

Century Therapeutics Presents Interim Results from Phase 1 ELiPSE-1 Study at ASCO 2024 Annual Meeting

In ongoing dose escalation, CNTY-101 has demonstrated a manageable safety profile with no observed DLTs or GvHD...

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form S-3 - Registration statement under Securities Act of 1933

Century Therapeutics Presents Preclinical Data Highlighting Advances in iPSC Platform Technology and Programs at 2024 ASGCT Annual Meeting

In vitro data showcases CNTY-101’s ability to induce CD19-specific cytolysis of B-cells and potential to treat...

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Century Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

- Announced plans to pursue additional autoimmune disease regulatory filings for its iPSC derived NK cell...

Form 4 - Statement of changes in beneficial ownership of securities